Bromantane
Limited human dataA Russian actoprotector that boosts dopamine synthesis — not a peptide, but a unique nootropic with real human data.
What it is
Bromantane (brand name Ladasten) is not a peptide. It is a synthetic small-molecule actoprotector developed in the Soviet Union in the 1980s. It is included here because it is widely discussed alongside nootropic peptides and fills a similar niche: cognitive enhancement, fatigue resistance, and anxiety reduction without sedation. Unlike most research chemicals, bromantane has a real human trial record, including published pharmacokinetics and controlled studies in asthenia (chronic fatigue syndrome).
How it works
Bromantane increases dopamine SYNTHESIS by upregulating tyrosine hydroxylase, the rate-limiting enzyme in dopamine production. It does not block reuptake or act as a releasing agent, which is why it produces no tolerance, no withdrawal, and a non-harsh profile. It also modulates the GABA/benzodiazepine receptor complex, contributing to its anxiolytic effect.
What people report
- ✦Medium: Reduction of asthenic symptoms; anxiety reduction without sedation
- ✦Low: Physical work capacity and recovery under heat or low oxygen; attention and operator performance during fatigue; durability of effect without tolerance or withdrawal
- ✦Speculative: Immune and inflammatory modulation; memory consolidation and synaptic plasticity
Typical use
Standard Russian regimen: 50–100 mg daily by mouth for up to 28 days; the low end applies for the first week. Best taken in the morning before 12:00. Peak blood levels 2.75 hours after dosing in women, 4.0 hours in men. Single morning dose — splitting is not described in any trial and pushes exposure into the evening.
Dosing reference
50–100 mg daily oral, morning only. Antiasthenic effects appear around day 3 and build over the first two weeks. The benefit persists roughly 1 month after stopping. No tolerance over two months of continuous rat dosing.
Reference only — not a recommendation. Verify via primary sources.
Watch for
Banned under WADA — athletes subject to anti-doping testing must avoid. Contraindicated with MAOIs, in bipolar/psychosis, uncontrolled hypertension, active liver disease, baseline cytopenias, and during pregnancy/breastfeeding. Key interactions include dopaminergic drugs, antipsychotics, barbiturates, OTC stimulants, sedating antihistamines, and serotonergic supplements. Monitoring: baseline blood work before a first course, repeat at end of each 28-day course, then every 6–12 months. Blood pressure and heart rate twice weekly throughout each course.
Notes
Not FDA-approved, research-use-only. Grey-market product quality is a real concern. Long-term safety data is limited. The anti-doping rule violation risk is the highest-consequence side effect.
Educational content — not medical advice.